Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two local anesthetics, bupivacaine and oxybuprocaine (also known as oxubuprocaine), used primarily for local or regional anesthesia. Both agents act by blocking voltage-gated sodium channels on neuronal membranes, thereby inhibiting the initiation and conduction of nerve impulses. Bupivacaine is an amide-type anesthetic with a long duration of action, commonly used for surgical anesthesia and pain management[2][3]. Oxybuprocaine is an ester-type anesthetic mainly used in ophthalmology to numb the surface of the eye during diagnostic or minor surgical procedures[1][8]. The combination may be considered when both rapid onset (from oxybuprocaine) and prolonged effect (from bupivacaine) are desired.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + oxybuprocaine.